HealthTide BiotechGHK-Cu
Ordered GHK-Cu from HealthTide Biotech? Mail in a sample (US only) and let us test it for free.
Test my supplyHealthTide Biotech GHK-Cu is limited by a 26 Feb 2026 fill failure: 56.2 mg in a 100 mg vial (-44%) despite identity pass and 99.9% purity. Earlier passes had -18% and -13% fills plus batch gaps, making quantity consistency the issue.
Archived B2B records tie HealthTide’s sales email domain to a Hong Kong-linked CONTIDE identity that later disappeared from ChemicalBook. The report also traces a parked storefront, US WhatsApp channel, and Texas-facing near-name reseller.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including HealthTide Biotech rows.
Cancel anytime
About HealthTide Biotech test results from Finnrick
HealthTide Biotech is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 3 peptides and 18 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible HealthTide Biotech peptides in this dataset are GHK-Cu (5 tests), Retatrutide (6 tests) and Tirzepatide (7 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 18 recent tests.
Ordered GHK-Cu from HealthTide Biotech? Mail in a sample (US only) and let us test it for free.
Test my supply